As one of the core technologies of precision medicine, Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) has significant advantages in detecting small molecular biomarkers and the potential to replace biochemical tests and immunoassay.
Calibra (Chinese: 凯莱谱), a precision health testing platform, completed a CNY 220 million (USD 33.22 million) Series B+ financing round led by CICC Jiatai Fund (Chinese:中金佳泰基金), with participation from Fosun Health Capital (Chinese: 复健资本), Qishen Venture Capital (Chinese:启申创投), Xihu Venture Capital (Chinese:西湖科创投) and CICC Pucheng Investment (Chinese:中金浦成).
China Renaissance (Chinese: 华兴资本) acted as the exclusive financial adviser for this round. The company closed a Series B financing round worth hundreds of millions of CNY in 2021, led by GL Ventures (Chinese:高瓴创投).
The company has made key progress and breakthroughs in the construction of multi-omics platform. Its new generation of high-end clinical mass spectrometry, CalQuant-S, was approved by NMPA in March 2022.
A host of class II reagent products, independently developed and produced by Disigns Diagnostics (Chinese:迪赛思诊断) under Calibra, have also been approved for sale, including immunosuppressants, steroid hormones, and fat-soluble vitamins.
The approval realized the overall solution of clinical mass spectrometry standardization and the full coverage of its closed-loop products.
At present, China lags behind in R&D, industrialization and application in the field of the mass spectrometer, which has been monopolized by global giants like Shimadzu, SCIEX, Thermo Fisher, Agilent and Waters.
However, some domestic LC-MS/MS manufacturers such as Yingsheng Biology (Chinese:英盛生物), MedicalSystem Medtechnology (Chinese:美康盛德医疗科技), Fenghua Biology (Chinese:丰华生物), Sym-Bio Life Science (Chinese:新波生物技术) have survived the domination of the giants and gained their market share.